Overview
Boutton holds an MSc and PhD from KU Leuven, researching protein behavior under high electromagnetic fields, and brings more than 20 years of antibody and biochemistry leadership. He joined Biotalys in May 2022 as Chief Scientific Officer, having previously served as Global Head of Innovation for Large Molecules Research at Sanofi and held scientific leadership roles at Ablynx (now Sanofi) and Tibotec (a Johnson and Johnson subsidiary). He assumed the interim CEO role following the departure of Kevin Helash.
Career history
- TibotecJ&J · anti-HIV and anti-HCV drug discovery
- Ablynxnow Sanofibioinformatics and protein modelling
- Sanofi, Global Head of Innovation Large Molecules Research
- Biotalys, CSOMay 2022Interim CEO (2026)
- FounderBiotalys
In the news
- I am excited to present an #AGROBODY biocontrol case study at this conference. Looking forward to a lively exchange with experts!
- Proud to see #EVOCA delivering strong results for growers in real-world conditions. A big thank you to all partners and Nico Vergote to coordinate these trials. We are now working hard on #EVOCA NG. Farmers need effective, sustainable solutions like this. #Biotalys #EVOCA #Agrobody
- Next Monday evening, 12 October, Biotalys' management will present an update on its activities and product pipeline to retail investors during a webinar organised by VFB vzw (Vlaamse Federatie van Beleggers). For more information and to register, please visit: https://lnkd.in/ecdNzwbc. The event will take place in Dutch. Carlo Boutton Luc Van fraeyenhoven #VFBSoirée #biocontrols #agtech #investing
- Trends TV currently runs an item on Biotalys' innovative technology to develop biobased crop protection products. Our scientists explain the value and the key principles of the AGROBODY® technology to come to protein-based products that are safe, sustainable and effective tools for growers. 🧪 Starring Carlo Boutton, Hélène Notredame and Rebecca De Cauwer.🌟 Click here for the video: https://lnkd.in/equFvVGV or watch it in the loop on Trends Z: https://lnkd.in/e-2Jyf2W until Monday evening 14 September 2026.
- Join our CEO Carlo Boutton and many other scientists and entrepreneurs for a session on bringing innovations to market, live in the Wintercircus Ghent on 27 October 2026. Register here: https://lnkd.in/ec3KpVi6
- Know what? Your research won't turn itself into a company. 🤯 That's why Biovia is joining VIB and Wintercircus Ghent for 𝗙𝗿𝗼𝗺 𝗟𝗮𝗯 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁, a free, hands-on session built for PhDs, postdocs, masters, #entrepreneurs and early #spinoffs ready to take the step from research to company. Lessons straight from the horse's mouth 🐴 🎤 Jorn Vanysacker (100IN) 🎤 Carlo Boutton (Biotalys) 🎤 Christel Menet (Confo Therapeutics) 🎤 Wim Van Criekinge (Ghent University) 🎤 Annick Verween (VIB) 🪩 And if you want to keep the
- We are very pleased to announce today that the California Department of Pesticide Regulation (CDPR) has granted state #registration for #EVOCA®, our first protein-based biofungicide. The approval follows the successful completion of the public consultation process earlier in July and confirms that the product has successfully met the state's stringent regulatory requirements for human #health, environmental #safety and product #efficacy. Carlo Boutton, Chief Executive Officer of Biotalys, commented: "This California registration
- In case you missed it during the holiday period: trade magazine GPN-Greenhouse Product News ran an article on the increase of #biological crop protection solutions in pest management programs, while positioning Biotalys as one of the key #innovators in the field. Many thanks to Keith Loria for speaking with our CEO Carlo Boutton. https://lnkd.in/gtvEybYR
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.